REACH- non-regulatory announcement

29 May 2025

Solvonis Therapeutics plc

("Solvonis" or the "Company")

Presentation at Mello2025

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of addiction and mental health disorders, is pleased to announce that the Company will be presenting at the Mello2025 investor event on Tuesday 3rd June 2025, to be held at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY.  Anthony Tennyson, CEO, will be presenting and will take questions during the event.

For further information and tickets (use code ShareM2550 for 50% off ticket price) for the Mello2025 conference, please visit the event website at www.melloevents.com/mello2025.

Enquiries:

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)
+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)
Phil Davies
+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of addiction and mental health disorders. Headquartered in London and listed on the Main Market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.

The Company's current focus is on Alcohol Use Disorder (AUD), which affects more than 40 million people across the US, UK, and EU4, and Post-Traumatic Stress Disorder (PTSD), impacting over 13million adults in the US and approximately 20 million across the same regions.

Solvonis has three core R&D programmes and a proprietary library of preclinical drug candidates:

1.    SVNS-001: A novel investigational combination therapy for the treatment of severe AUD, currently in Phase 3 clinical development. In a prior Phase 2 study, participants in the active treatment arm achieved 86% abstinence from alcohol in the six months post-treatment, compared to just 2% pre-trial.

A market analysis commissioned by Solvonis and conducted by PharmaVentures indicates that comparable late-stage UK/EU-focused assets in the substance use disorder space typically achieve total deal values of ~£60 million in upfront and milestone payments, in addition to royalties on net sales if successfully out licensed.

2.    SVNS-002: A proprietary, investigational, patent-pending sublingual/buccal esketamine formulation for use in combination with manualised therapy in treating moderate to severe AUD. This programme is in Phase 2b planning in the US and is expected to follow the FDA's 505(b)(2) regulatory pathway.

PharmaVentures estimates that, following successful Phase 2b completion, comparable mid-stage assets typically achieve total deal values of ~£150 million, plus future royalties if out licensed.

3.    SVNS-SDN-14: A novel series of serotonin, dopamine, and noradrenaline receptor modulators, currently at preclinical stage, being developed to promote pro-social behavior and improve upon the safety profile of existing investigational PTSD treatments.

In addition to these lead programmes, Solvonis owns a proprietary library of preclinical compounds, each having completed hit-to-lead progression, with composition-of-matter patents filed across multiple chemical series.

www.solvonis.com | LinkedIn | X (formerly Twitter) 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted companies to distribute media only / non-regulatory news releases into the public domain.  Information required to be notified under the Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.